Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.

Mepolizumab significantly improved nasal obstruction VAS score from baseline to weeks 49–52 compared with placebo, with a mean treatment difference of −1.43, and showed a numerical trend toward improvement in total endoscopic nasal polyp score at week 52, with a mean treatment difference of −0.43 ( 107 ).

also in 723 other papers

Improvements in Sinonasal Outcome Test-22 (SNOT-22) score at week 40, time to first nasal polyp surgery and/or systemic corticosteroid use for nasal polyps, and time to first nasal polyp surgery did not reach statistical significance, whereas improvement in sense-of-smell score reached nominal significance ( 109 ).

also in 75,281 other papers